Efficacy and safety of direct oral anticoagulants versus enoxaparin for extended thromboprophylaxis following sleeve gastrectomy
- 11 February 2026
- journal article
- research article
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (5) , 473-481
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Center for Advancing Translational Sciences
- New York University (KL2 TR001446)
This publication has 34 references indexed in Scilit:
- Parathyroidectomy and Risk of Incident Diabetes in Patients With Primary HyperparathyroidismJAMA Surgery, 2025
- Comparison between low molecular weight heparin and apixaban (direct oral anticoagulant) in the prophylaxis against venous thromboembolism after laparoscopic sleeve gastrectomyObesity Surgery, 2025
- Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric SurgeryObesity Surgery, 2024
- Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric SurgeryJAMA Network Open, 2023
- 30-Day Post-Discharge Prophylaxis with Rivaroxaban Prevents Porto-mesenteric Venous Thrombosis Following Laparoscopic Sleeve GastrectomyObesity Surgery, 2023
- Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric SurgeryObesity Surgery, 2021
- Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case seriesJournal of Thrombosis and Thrombolysis, 2021
- Association of Coronary Artery Bypass Grafting vs Percutaneous Coronary Intervention With Memory Decline in Older Adults Undergoing Coronary RevascularizationJAMA, 2021
- Perioperative complications increase the risk of venous thromboembolism following bariatric surgeryThe American Journal of Surgery, 2017
- Incidence of Venous Thromboembolism After Bariatric Surgery: A Population-Based Cohort StudyObesity Surgery, 2013